External Counterpulsation Devices Market Size, Share and Industry Analysis By Product (Device and Accessories), By Mobility (Fixed and Portable), By Indication (Angina Pectoris, Heart Failure, Left Ventricular Dysfunction, Peripheral Artery (Vascular) Disease, and Others), By End-user (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast, 2025-2032

External counterpulsation devices (ECPs), are used to perform external counterpulsation therapies, which is a non-invasive method that is performed to help in lowering the intensity of heart conditions such as angina pectoris. The treatment is done with the help of pressure cuffs which are wrapped around the patient's legs, thighs, calves, and others, which inflate and deflate at specific times between the heartbeats. Therefore, the increasing prevalence of cardiovascular diseases, such as angina pectoris, heart failure, left ventricular dysfunction, and others, have been fueling the demand for external counterpulsation devices.

• For instance, as per a study published by the National Center for Biotechnology Information (NCBI) in June 2023, approximately 9 million patients in the U.S. have symptoms of angina, and chronic stable angina affects approximately 30,000 to 40,000 people per million people in Western countries.               

Moreover, the increasing launch of external counterpulsation centers and the growing use of external counterpulsation devices for the treatment of various diseases have also been fueling the market growth.

The global external counterpulsation devices market experienced a decline in its market value during the COVID-19 pandemic in 2020 due to the lesser number of patient visits to hospitals for external counterpulsation therapies. Furthermore, various lockdown restrictions were posed by many countries, which resulted in a disruption in the supply chain. For instance, in the year 2020, Vamed Medical Instrument Co., Ltd, reported a decline of 6.3% in its revenue from the prior year due to the pandemic.

However, the market grew at a significant growth rate in 2021 and 2022 as external counterpulsation devices were used extensively in various research studies to evaluate its potential in treating the symptoms related to COVID-19 such as fatigue, breathing difficulties, and chest discomfort.

For instance, in February 2022, a study published by the American College of Cardiology Foundation, in a study of long COVID-19 patients, demonstrated the improvement of symptoms such as fatigue, breathing difficulties and chest discomfort after undergoing 15-35 hours of enhanced external counterpulsation (EECP) therapy.

Key Insights

The report covers the following key insights:

• Prevalence of Cardiovascular Disorders - by Key Countries/Sub-region, 2022/2023
• Technological Advancements in External Counterpulsation Devices
• Overview of Regulatory Scenario for Medical Devices – By Key Countries/Sub-region
• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
• Impact of COVID-19 on the External Counterpulsation Devices Market

Segmentation

Analysis by Product

On the basis of product, the device segment accounted for a significant market share in 2023. The growth of the segment is attributed to the increased use of external counterpulsation devices in research studies for evaluating its potential in treating the symptoms related to COVID-19.

• For instance, in January 2024, according to a study published in the American Journal of Physical Medicine & Rehabilitation, a study conducted on patients with long COVID and objectively assessed cognitive impairment showed that enhanced external counterpulsation devices led to significant improvement in cognitive functioning of long COVID patients with objectively defined cognitive impairment.

Moreover, the accessories segment is expected to grow at a substantial CAGR during the forecast period. The segment growth is attributed to the increasing prevalence of angina pectoris and the rising demand for external counterpulsation therapies.

Regional Analysis

North America is projected to account for a significant share of the global external counterpulsation devices market in 2023. The regional growth is attributed to the strong presence of market players such as Vaso Corporation, ACS Diagnostics, and others. The increasing use of external counterpulsation devices for the treatment of various diseases such as heart failure, left ventricular dysfunction, cerebrovascular diseases, and others, and the increasing prevalence of these diseases is expected to drive market growth.

• For instance, in September 2023, according to a study published in the Journal of Cardiac Failure, approximately 6.7 million people in the U.S. over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.5 million Americans by 2030.

Moreover, the market in Europe is expected to grow at a significant CAGR during the forecast period. The regional growth is attributed to the focus of market players on the launch of cardiac centers and the increasing prevalence of cardiovascular diseases. For instance, in October 2023, Mediport, an innovative healthcare provider, opened its new multidisciplinary healthcare center in Belgium, Europe. The facility includes GE HealthCare’s first One-Stop Clinic for Cardiology, which represents an innovative pathway to diagnose cardiovascular disease within one day.

Key Players Covered

The report includes the profiles of key players such as Vamed Medical Instrument Co., Ltd, ACS Diagnostics, CardioMedics, Inc., Renew Group Private Limited, Shanghai Goodmed Medical Device Co., Limited, ScottCare Cardiovascular Solutions, Vaso Corporation, and ANAND MEDITECH.

Key Industry Developments

• In June 2022, Heal Your Heart, a company specializing in non-invasive heart surgery EECP treatment, inaugurated its new enhanced external counterpulsation center in Neelankarai, India. The center is a nine-room EECP treatment facility, which makes it the largest EECP treatment center in India.

In February 2020, Enso S&A Health House Sdn. Bhd. (Enso) partnered with My Life Centre (MLC) to open two more new external counterpulsation (ECP) centers in Johor Bahru & Kota Bahru, Malaysia for alternative medicine and therapy.